34 related articles for article (PubMed ID: 11324501)
1. Molecular-based classification algorithm for endometrial carcinoma categorizes ovarian endometrioid carcinoma into prognostically significant groups.
Parra-Herran C; Lerner-Ellis J; Xu B; Khalouei S; Bassiouny D; Cesari M; Ismiil N; Nofech-Mozes S
Mod Pathol; 2017 Dec; 30(12):1748-1759. PubMed ID: 28776572
[TBL] [Abstract][Full Text] [Related]
2. Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells.
Momeny M; Zarrinrad G; Moghaddaskho F; Poursheikhani A; Sankanian G; Zaghal A; Mirshahvaladi S; Esmaeili F; Eyvani H; Barghi F; Sabourinejad Z; Alishahi Z; Yousefi H; Ghasemi R; Dardaei L; Bashash D; Chahardouli B; Dehpour AR; Tavakkoly-Bazzaz J; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Sci Rep; 2017 Jun; 7(1):4204. PubMed ID: 28646172
[TBL] [Abstract][Full Text] [Related]
3. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
[TBL] [Abstract][Full Text] [Related]
4. Effects of silibinin on growth and invasive properties of human ovarian carcinoma cells through suppression of heregulin/HER3 pathway.
Momeny M; Ghasemi R; Valenti G; Miranda M; Zekri A; Zarrinrad G; Javadikooshesh S; Yaghmaie M; Alimoghaddam K; Ghavamzadeh A; Ghaffari SH
Tumour Biol; 2016 Mar; 37(3):3913-23. PubMed ID: 26482609
[TBL] [Abstract][Full Text] [Related]
5. High incidence of ErbB3, ErbB4, and MET expression in ovarian cancer.
Davies S; Holmes A; Lomo L; Steinkamp MP; Kang H; Muller CY; Wilson BS
Int J Gynecol Pathol; 2014 Jul; 33(4):402-10. PubMed ID: 24901400
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic protein biomarkers in epithelial ovarian cancer: recommendation for future studies.
Le Page C; Huntsman DG; Provencher DM; Mes-Masson AM
Cancers (Basel); 2010 May; 2(2):913-54. PubMed ID: 24281100
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of several biomarkers in epithelial ovarian cancer: a meta-analysis of published studies.
Xu L; Cai J; Yang Q; Ding H; Wu L; Li T; Wang Z
J Cancer Res Clin Oncol; 2013 Aug; 139(8):1257-77. PubMed ID: 23595127
[TBL] [Abstract][Full Text] [Related]
8. EGFR/HER-targeted therapeutics in ovarian cancer.
Wilken JA; Badri T; Cross S; Raji R; Santin AD; Schwartz P; Branscum AJ; Baron AT; Sakhitab AI; Maihle NJ
Future Med Chem; 2012 Mar; 4(4):447-69. PubMed ID: 22416774
[TBL] [Abstract][Full Text] [Related]
9. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.
Amin DN; Campbell MR; Moasser MM
Semin Cell Dev Biol; 2010 Dec; 21(9):944-50. PubMed ID: 20816829
[TBL] [Abstract][Full Text] [Related]
10. An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.
Sheng Q; Liu X; Fleming E; Yuan K; Piao H; Chen J; Moustafa Z; Thomas RK; Greulich H; Schinzel A; Zaghlul S; Batt D; Ettenberg S; Meyerson M; Schoeberl B; Kung AL; Hahn WC; Drapkin R; Livingston DM; Liu JF
Cancer Cell; 2010 Mar; 17(3):298-310. PubMed ID: 20227043
[TBL] [Abstract][Full Text] [Related]
11. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy.
Campbell MR; Amin D; Moasser MM
Clin Cancer Res; 2010 Mar; 16(5):1373-83. PubMed ID: 20179223
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer: their relationship with clinicopathological parameters and prognostic significance.
Yu GZ; Chen Y; Wang JJ
J Cancer Res Clin Oncol; 2009 Oct; 135(10):1331-9. PubMed ID: 19337752
[TBL] [Abstract][Full Text] [Related]
13. The ERBB3 receptor in cancer and cancer gene therapy.
Sithanandam G; Anderson LM
Cancer Gene Ther; 2008 Jul; 15(7):413-48. PubMed ID: 18404164
[TBL] [Abstract][Full Text] [Related]
14. Bone microenvironment and androgen status modulate subcellular localization of ErbB3 in prostate cancer cells.
Cheng CJ; Ye XC; Vakar-Lopez F; Kim J; Tu SM; Chen DT; Navone NM; Yu-Lee LY; Lin SH; Hu MC
Mol Cancer Res; 2007 Jul; 5(7):675-84. PubMed ID: 17634423
[TBL] [Abstract][Full Text] [Related]
15. Biologic directed therapies in gynecologic oncology.
Farley JH; Birrer MJ
Curr Oncol Rep; 2003 Nov; 5(6):459-67. PubMed ID: 14521804
[TBL] [Abstract][Full Text] [Related]
16. The role of epidermal growth factor receptor in head and neck squamous cell carcinoma.
Pomerantz RG; Grandis JR
Curr Oncol Rep; 2003 Mar; 5(2):140-6. PubMed ID: 12583831
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of p53, EGFR, c-erbB2 and c-erbB3 in endometrioid carcinoma of the ovary.
Leng J; Lang J; Shen K; Guo L
Chin Med Sci J; 1997 Jun; 12(2):67-70. PubMed ID: 11324501
[TBL] [Abstract][Full Text] [Related]
18. [Expression of epidermal growth factor receptor (EGFR) in endometrioid carcinoma of the ovary].
Leng J; Lang J; Guo L
Zhonghua Yi Xue Za Zhi; 1996 Apr; 76(4):281-3. PubMed ID: 8758275
[TBL] [Abstract][Full Text] [Related]
19. [Expression of P53, P63, and C-erbB-2 in endometrioid adenocarcinoma and their clinicopathological significance].
Hu WF; Liu MQ; Zhao Q
Ai Zheng; 2004 Sep; 23(9):1021-5. PubMed ID: 15363194
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
